C2orf54 Inhibitors
Brefeldin A and thapsigargin can disrupt normal protein trafficking and calcium homeostasis, respectively, which are both critical for the maintenance of protein function and could thus affect CCDC142 indirectly. Similarly, tunicamycin, by inhibiting proper glycosylation, can lead to misfolded proteins, potentially impacting the stability or localization of CCDC142. The proteasome inhibitor MG-132 can increase the half-life of proteins, including potentially CCDC142, by preventing their degradation.
Cycloheximide, on the other hand, can decrease CCDC142 expression by inhibiting its synthesis. Compounds like PD 98059, U0126, LY294002, and rapamycin target key signaling pathways, such as MAPK/ERK and PI3K/Akt/mTOR, which are integral to the regulation of various cellular functions and may indirectly modulate the activity of CCDC142. Epigenetic modifiers like 5-Azacytidine and Trichostatin A can change the expression levels of genes, including those encoding for CCDC142, by altering the methylation and acetylation status of DNA and histones, respectively.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that can disrupt multiple signaling pathways, potentially influencing CCDC142 activity by altering its phosphorylation state. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
A substance that can disrupt protein transport by inhibiting ADP-ribosylation factor, potentially affecting CCDC142 localization and function. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
An inhibitor of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) that can influence calcium homeostasis, possibly affecting CCDC142 activity. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
An N-linked glycosylation inhibitor that can affect protein folding and thus potentially alter CCDC142 folding or stability. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor that can increase the levels of proteins by preventing their degradation, potentially affecting CCDC142 turnover. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
An inhibitor of protein biosynthesis that can decrease overall protein levels, potentially affecting CCDC142 expression indirectly. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An inhibitor of MEK which is part of the MAPK/ERK pathway, potentially altering signaling pathways that CCDC142 is part of. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
Another MEK inhibitor that can modulate the MAPK/ERK pathway and potentially affect CCDC142-associated processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that can influence the PI3K/Akt pathway, potentially impacting CCDC142's role within the cell. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can disrupt downstream signaling pathways, potentially influencing CCDC142's activity. | ||||||